Niki BioSolutions, Inc. appointed Thomas Freeburg as Chief Financial Officer for a two-year term effective September 1, 2026. Mr. Freeburg's compensation package includes a base salary of $250,000 (increasing to $275,000 upon certain funding), an annual bonus of up to 50%, and 50,000 stock options at an exercise price of $8.83 per share.
Niki BioSolutions, Inc. entered into an At the Market Offering Agreement with H.C. Wainwright & Co. and Brookline Capital Markets to establish an ATM program. The company may sell shares of common stock from time to time up to an aggregate maximum offering price of $1.396 million, though no shares have been sold as of the filing date.
Niki BioSolutions filed its corporate PowerPoint presentation which was presented by President & COO Alidad Mireskandari at the H.C. Wainwright Global Investment Conference in September 2026. The presentation highlights the company's recent all-stock merger with DiamiR Biosciences, which was completed on July 20, 2026.